Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358617 · ClinicalTrials.gov registry record
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma
A clinical trial, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 90
- Enrollment target
NCT01358617: Completed study, sponsored by Children's Oncology Group.
NCT01358617 is a clinical trial that has completed, run by Children's Oncology Group. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01358617 has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
This research study is studying biomarkers in tumor tissue samples from young patients with neuroblastoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors identify biomarkers and learn more about biomarkers related to cancer
Interventions
- OTHER diagnostic laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-08 |
What the finished NCT01358617 record still lists
NCT01358617 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which diagnostic laboratory biomarker analysis is the first listed.
NCT01358617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01358617 about?
NCT01358617 is a clinical study titled "Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma". This research study is studying biomarkers in tumor tissue samples from young patients with neuroblastoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors identify biomarkers and learn more about biomarkers related to cancer
What is the current status of trial NCT01358617?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2011-05. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01358617?
The interventions under investigation include: diagnostic laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT01358617?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia